Namaste Technologies (CSE:N; OTCMKTS:NXTTF) announced it obtained final approval to list its common shares and warrants on the TSX Venture Exchange.

As quoted in the press release:


The common shares and warrants of the Company will be delisted from the Canadian Securities Exchange at the close of trading on May 1, 2018 and listed on the TSXV at the opening of trading on May 2, 2018. The Company’s common shares will continue to trade under the symbol “N” and its warrants will continue to trade under the symbol “N.WT.” The Company believes that listing on the TSXV will provide Namaste and its shareholders with many advantages, including greater visibility and enhanced market access for Canadian and international investors.

Management Commentary

Sean Dollinger, President and CEO of Namaste comments: “We are very pleased to have received final approval to list on the TSXV as a Tier 1 issuer. We’re proud to have reached a point where the Company will gain more exposure through a larger market and to join many of our peers on the TSXV. We’d like to thank our shareholders and management team for their continued support. This is certainly an exciting day in the history of Namaste and we look forward to a bright future.”

Click here to read the full press release.

Source: marijuanaindex.com

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at VirtualInvestorConferences.com on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less

Achievements with Scalability and Compatibility Pave Way for Next Phase of Advancement

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is excited to announce that the Company’s holding, Arcology, a cluster-computing powered AI blockchain ecosystem with unlimited scalability, has updated its working roadmap in response to its Testnet 1.0 results

Keep reading... Show less